Nektar Therapeutics (OQ:NKTR)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 455 Mission Bay Blvd S
SAN FRANCISCO CA 94158-2158
Tel: 1-415-4825585
Website: www.nektar.com
IR: See website
<
Key People
Robert B. Chess
Independent Chairman of the Board
Howard W. Robin
President, Chief Executive Officer, Director
Gilbert M. Labrucherie
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Jillian B. Thomsen
Senior Vice President - Finance, Chief Accounting Officer
Wei Lin
Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs
John Northcott
Senior Vice President and Chief Commercial Officer
Jonathan Zalevsky
Chief Research & Development Officer
   
Business Overview
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
Financial Overview
For the fiscal year ended 31 December 2019, Nektar Therapeutics revenues decreased 90% to $114.6M. Net loss before extraordinary items totaled $440.6M vs. income of $681.4M. Revenues reflect United States segment decrease of 98% to $27.1M, European Countries segment decrease of 15% to $87.5M. Net loss reflects Research and development - Balancing val increase of 8% to $371.3M (expense).
Employees: 723 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $2,131M as of Dec 31, 2019
Annual revenue (TTM): $114.62M as of Dec 31, 2019
EBITDA (TTM): -$426.88M as of Dec 31, 2019
Net annual income (TTM): -$440.64M as of Dec 31, 2019
Free cash flow (TTM): -$354.97M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 177,557,144 as of Feb 19, 2020
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization